OAR 333-007-0430
Standards for THC and CBD Compliance Testing

(1) A laboratory must test for the following when testing a marijuana item for potency:
(a) THC.
(b) THCA.
(c) CBD.
(d) CBDA.
(2) A process lot of a cannabinoid concentrate, extract or product that has not successfully completed a control study fails potency testing if, based on an initial test where no reanalysis is requested or upon reanalysis as described in OAR 333-007-0450 (Failed Test Samples)(1):
(a) The amount of THC and CBD, as calculated pursuant to OAR 333-064-0100 (Marijuana Item Sampling Procedures and Testing), between samples taken from the batch exceeds 20 percent RSD; or
(b) The amount or percentage of THC, as calculated pursuant to OAR 333-064-0100 (Marijuana Item Sampling Procedures and Testing) for any sample increment, exceeds the maximum concentration limits permitted in package by over 10 percent as specified in OAR 333-007-0200 (Concentration and Serving Size Limits: Definitions, Purpose, Scope and Effective Date) to 333-007-0220 (Medical Marijuana Item Concentration Limits), as applicable.
(3) A process lot of a cannabinoid concentrate, extract or product that has successfully completed a control study fails potency testing if, based on an initial test where no reanalysis is requested or upon reanalysis as described in OAR 333-007-0450 (Failed Test Samples)(1):
(a) The amount of THC or CBD, as calculated pursuant to OAR 333-064-0100 (Marijuana Item Sampling Procedures and Testing), between the primary sample and the field duplicate exceeds 15 percent RPD; or
(b) The amount or percentage of THC, as calculated pursuant to OAR 333-064-0100 (Marijuana Item Sampling Procedures and Testing), exceeds the maximum concentration limits permitted in a package by over 10 percent as specified in OAR 333-007-0200 (Concentration and Serving Size Limits: Definitions, Purpose, Scope and Effective Date) to 333-007-0220 (Medical Marijuana Item Concentration Limits), as applicable
(4) Notwithstanding subsection (2)(a) and (3)(a) of this rule:
(a) A cannabinoid product that has less than 5 mg of THC per unit of sale as calculated pursuant to OAR 333-064-0100 (Marijuana Item Sampling Procedures and Testing) does not fail potency testing based on exceedance of the RSD or RPD as described in subsection (2)(a) or (3)(a) of this rule.
(b) A cannabinoid product that has less than 5 mg of CBD per unit of sale as calculated pursuant to OAR 333-064-0100 (Marijuana Item Sampling Procedures and Testing) does not fail potency testing based on exceedance of the RSD or RPD as described in subsection (2)(a) or (3)(a) of this rule.
(c) A cannabinoid concentrate or extract that has less than 5 mg THC per gram as calculated pursuant to OAR 333-064-0100 (Marijuana Item Sampling Procedures and Testing) does not fail potency testing based on exceedance of the RSD or RPD as described in subsection (2)(a) or (3)(a) of this rule.
(d) A cannabinoid concentrate or extract that has less than 5 mg CBD per gram as calculated pursuant to OAR 333-064-0100 (Marijuana Item Sampling Procedures and Testing) does not fail potency testing based on exceedance of the RSD or RPD as described in subsection (2)(a) or (3)(a) of this rule.

Source: Rule 333-007-0430 — Standards for THC and CBD Compliance Testing, https://secure.­sos.­state.­or.­us/oard/view.­action?ruleNumber=333-007-0430.

Last Updated

Jun. 8, 2021

Rule 333-007-0430’s source at or​.us